
April 10, 2013

NASDAQ OMX Welcomes NeuroVive to the Main Market

Stockholm, April 10, 2013 — NASDAQ OMX (NASDAQ:NDAQ) announced that NeuroVive Pharmaceutical AB (“NeuroVive”), a Small Cap company within the Healthcare sector, today starts trading of its shares on the main market of NASDAQ OMX Stockholm. NeuroVive was previously listed on Aktietorget and is the first company to list on NASDAQ OMX Nordic main markets this year. NeuroVive will continue to trade under the same ticker symbol, NVP.

NeuroVive is a leading mitochondrial medicine company that is developing a portfolio of products to treat acute cardiovascular and neurological conditions through mitochondrial protection. Its products, CicloMulsion® and NeuroSTAT®, are special formulations of the cyclophilin inhibitor cyclosporine for two prioritized indications, the prevention of reperfusion injury following stenting after myocardial infarction and traumatic brain injury respectively. CicloMulsion® is currently in a 1,000 patient Phase III trial assessing its ability to reduce overall mortality and the number of patients developing heart failure in patients with myocardial infarction. NeuroSTAT® is soon entering a Phase II clinical trial in patients with traumatic brain injury. For more information, please visit www.neurovive.com.

“Our move to NASDAQ OMX Stockholm is an important step forward in the growth and development of our company,” said Mikael Bronnegard, CEO of NeuroVive. “Through this listing NeuroVive will gain international exposure and access to a broader and deeper pool of investors that will be vital as we look to finance our strategy which is designed to maximize shareholder value from our leading position in mitochondrial medicine.”

“NeuroVive operates in a market space with significant potential and will make an exciting addition to our healthcare sector and our main market,” said Adam Kostyal, Senior Vice President at NASDAQ OMX. “NeuroVive is one of several companies listed at alternative growth markets that have opted for a switch to NASDAQ OMX in order to take advantage of the unique investor exposure and strong liquidity that we offer.”

To view a CEO interview from the NeuroVive listing ceremony [click here](#).

- # -

About NASDAQ OMX

The inventor of the electronic exchange, The NASDAQ OMX Group, Inc., fuels economies and provides transformative technologies for the entire lifecycle of a trade - from risk management to trade to surveillance to clearing. In the U.S. and Europe, we own and operate 24 markets, 3 clearinghouses and 5 central securities depositories supporting equities, options, fixed income, derivatives, commodities, futures and structured products.

Able to process more than 1 million messages per second at sub-40 microsecond speeds with 99.999% uptime, our technology drives more than 70 marketplaces in 50 developed and emerging countries into the future, powering 1 in 10 of the world's securities transactions. Our award-winning data products and worldwide indexes are the benchmarks in the financial industry. Home to approximately 3,400 listed companies worth \$6 trillion in market cap whose innovations shape our world, we give the ideas of tomorrow access to capital today. Welcome to where the world takes a big leap forward, daily. Welcome to the NASDAQ OMX Century. To learn more, visit www.nasdaqomx.com. Follow us on Facebook (<http://www.facebook.com/NASDAQ>) and Twitter (<http://www.twitter.com/nasdaqomx>). (Symbol: NDAQ and member of S&P 500)

Cautionary Note Regarding Forward-Looking Statements

The matters described herein contain forward-looking statements that are made under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about NASDAQ OMX's acquisition of the eSpeed platform, the benefits of the transaction, the U.S. Treasury market, the proposed financing, the implementation date of the transaction, NASDAQ OMX's plans, objectives, expectations and intentions and other statements that are not historical facts. We caution that these statements are not guarantees of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements involve a number of risks, uncertainties or other factors beyond NASDAQ OMX's control. These factors include, but are not limited to factors detailed in NASDAQ OMX's annual report on Form 10-K, and periodic reports filed with the U.S. Securities and Exchange Commission. We undertake no obligation to release any revisions to any forward-looking statements.

Media contact:

Carl Norell

+46 8 405 66 39

carl.norell@nasdaqomx.com